Vivani Medical, Inc. (VANI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vivani Medical, Inc. (VANI) trades at $1.29 with AI Score 27/100 (Grade F). Vivani Medical, Inc. is a clinical-stage company focused on developing miniature drug implants for chronic diseases and implantable visual prostheses. Market cap: $76.51M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026VANI stock analysis for 2026: Analysts have set a consensus price target of $4.83 for Vivani Medical, Inc., suggesting 273.2% upside from the current price of $1.29. The AI MoonshotScore is 27/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
VANI: 5/7 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Vivani Medical, Inc. (VANI) Healthcare & Pipeline Overview
Vivani Medical, Inc. is a clinical-stage medical device company specializing in innovative implantable technologies for chronic diseases and vision impairment. Their focus on miniature drug implants delivering stable drug profiles and visual prostheses positions them in a high-need segment of the healthcare market, targeting improved patient outcomes.
What Is the Investment Thesis for VANI?
Vivani Medical, Inc. presents a notable research candidate within the medical device sector, driven by its focus on innovative implantable technologies. The company's development of miniature drug implants for chronic diseases and visual prostheses addresses significant unmet medical needs. Key value drivers include successful clinical trial outcomes, regulatory approvals, and strategic partnerships. The company's ability to demonstrate the efficacy and safety of its implantable devices will be crucial for market adoption and revenue generation. However, potential risks include clinical trial failures, regulatory hurdles, and competition from established medical device companies. The company's market capitalization is approximately $0.07 billion, reflecting its early-stage nature and growth potential.
Based on FMP financials and quantitative analysis
VANI Key Highlights
- Vivani Medical is a clinical-stage company focused on implantable medical devices.
- The company is developing miniature drug implants for chronic diseases.
- Vivani Medical is also working on implantable visual prostheses for blind individuals.
- The company aims to deliver minimally fluctuating drug profiles with its implants.
- Vivani Medical is headquartered in Emeryville, California, with 37 employees.
Who Are VANI's Competitors?
VANI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
| AXGN AxoGen, Inc. | $45.08 | -1.77% | $2.40B | 58 |
| NXL Nexalin Technology, Inc. | $0.35 | -3.07% | $7.20M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VANI's Key Strengths?
- Innovative implantable device technology.
- Focus on high unmet medical needs.
- Experienced management team.
- Strong intellectual property portfolio.
What Are VANI's Weaknesses?
- Clinical-stage company with limited revenue.
- Reliance on successful clinical trial outcomes.
- Dependence on regulatory approvals.
- Limited financial resources.
What Could Drive VANI Stock Higher?
- Clinical trial results for lead drug implant candidate.
- FDA regulatory submission for visual prostheses device.
- Strategic partnership discussions with pharmaceutical companies.
- Expansion of intellectual property portfolio.
What Are the Key Risks for VANI?
- Financial-distress signal — its Altman Z-Score of -4.91 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures may delay or halt product development.
- Regulatory hurdles may delay or prevent product approvals.
- Competition from established medical device companies may limit market share.
- Limited financial resources may constrain growth opportunities.
What Are the Growth Opportunities for VANI?
- Expansion into New Therapeutic Areas: Vivani Medical can leverage its expertise in implantable drug delivery to expand into new therapeutic areas beyond its current focus. This could include developing implants for pain management, neurological disorders, or other chronic conditions. The market for implantable drug delivery systems is projected to reach billions of dollars in the coming years, offering significant growth potential for Vivani Medical. Success hinges on identifying suitable therapeutic targets and demonstrating the efficacy and safety of its implants in these new areas.
- Strategic Partnerships and Collaborations: Vivani Medical can pursue strategic partnerships and collaborations with pharmaceutical companies, research institutions, and other medical device companies to accelerate its product development and commercialization efforts. Collaborations can provide access to new technologies, funding, and market expertise. For example, partnering with a pharmaceutical company could enable Vivani Medical to develop implants that deliver proprietary drugs, creating a unique and competitive product offering. These partnerships can de-risk development and speed time to market.
- Geographic Expansion: Vivani Medical can expand its geographic reach beyond the United States by targeting international markets with high unmet medical needs. This could involve seeking regulatory approvals in Europe, Asia, and other regions, and establishing distribution networks to reach patients in these markets. Geographic expansion can significantly increase Vivani Medical's revenue potential and diversify its revenue streams. However, it also requires navigating different regulatory environments and cultural nuances.
- Advancements in Visual Prostheses Technology: Vivani Medical has the opportunity to further develop its implantable visual prostheses technology to improve the quality of artificial vision provided to blind individuals. This could involve incorporating new sensors, algorithms, and stimulation techniques to enhance the resolution, contrast, and field of view of the prostheses. Advancements in visual prostheses technology can significantly improve the lives of blind individuals and create a strong competitive advantage for Vivani Medical.
- Data Analytics and Personalized Medicine: Vivani Medical can leverage data analytics and personalized medicine approaches to optimize the performance of its implantable devices and tailor treatment to individual patient needs. This could involve collecting data on patient responses to drug delivery or visual stimulation, and using this data to refine the design and programming of its implants. Personalized medicine approaches can improve treatment outcomes and patient satisfaction, and differentiate Vivani Medical from its competitors.
What Opportunities Does VANI Have?
- Expansion into new therapeutic areas.
- Strategic partnerships and collaborations.
- Geographic expansion.
- Advancements in implantable device technology.
What Threats Does VANI Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established medical device companies.
- Product liability claims.
What Are VANI's Competitive Advantages?
- Proprietary implantable device technology.
- Focus on niche markets with high unmet medical needs.
- Intellectual property protection through patents and trade secrets.
- Established relationships with key opinion leaders and healthcare providers.
What Does VANI Do?
Vivani Medical, Inc. is a clinical-stage company dedicated to the development and commercialization of innovative implantable medical devices. The company focuses on addressing chronic diseases with high unmet medical needs through miniature drug implants designed to deliver minimally fluctuating drug profiles. Additionally, Vivani Medical is developing implantable visual prostheses aimed at restoring useful artificial vision to individuals suffering from blindness. The company's portfolio reflects a commitment to leveraging advanced technology to improve patient outcomes and quality of life. Headquartered in Emeryville, California, Vivani Medical operates with a team of 37 employees. The company is focused on advancing its pipeline of implantable devices through clinical trials and regulatory approvals, with the goal of bringing novel treatment options to market. Their strategic focus on implantable technologies allows for precise and sustained drug delivery, potentially reducing the need for frequent injections or oral medications, and offering a more convenient and effective treatment approach for patients with chronic conditions.
What Products and Services Does VANI Offer?
- Develops miniature drug implants for chronic diseases.
- Creates implantable visual prostheses for blind individuals.
- Focuses on delivering minimally fluctuating drug profiles.
- Aims to restore useful artificial vision to individuals with blindness.
- Conducts clinical trials to evaluate the safety and efficacy of its devices.
- Seeks regulatory approvals for its products.
How Does VANI Make Money?
- Develops and manufactures implantable medical devices.
- Conducts clinical trials to demonstrate the safety and efficacy of its devices.
- Seeks regulatory approvals from agencies like the FDA.
- Commercializes its products through direct sales or partnerships.
What Industry Does VANI Operate In?
Vivani Medical operates within the medical device industry, a sector characterized by rapid innovation and technological advancements. The market for implantable medical devices is experiencing growth, driven by an aging population and increasing prevalence of chronic diseases. Competition is intense, with established players and emerging companies vying for market share. Vivani Medical's focus on miniature drug implants and visual prostheses positions it within a niche segment of the market, offering potential for differentiation and growth. The company's success will depend on its ability to navigate regulatory pathways, secure funding, and establish strategic partnerships.
Who Are VANI's Key Customers?
- Patients with chronic diseases requiring long-term drug delivery.
- Individuals suffering from blindness seeking artificial vision solutions.
- Healthcare providers who prescribe and implant Vivani Medical's devices.
- Hospitals and clinics that offer Vivani Medical's products.
Company Profile
Vivani Medical, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Alameda, US. The company is led by CEO Adam Mendelsohn. VANI has traded publicly since 2014.
F-Score 2/9Financial Health
Vivani Medical, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.91 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -64.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -35.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.18 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -26.5%, the inverse of the P/E and a quick read on earnings relative to price.
VANI Valuation & Market Position
With a $76.51M market cap, Vivani Medical, Inc. sits in the micro-cap segment of the market. Relative to its peer group, VANI's quantitative score of 27/100 is below the peer average of 69/100.
FY2026 estForward Outlook
Wall Street analysts project Vivani Medical, Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.34.
VANI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider purchases suggest confidence in Vivani's growth trajectory, reflecting a belief in its innovative pipeline.
- Community sentiment has turned positive as new partnerships in the medical device space are generating buzz.
- The company's focus on advancing diabetes management solutions aligns well with increasing market demand for effective treatments.
- Recent press releases highlight advancements in technology that could position Vivani as a leader in its niche.
Bear Case
- Some analysts express skepticism about the scalability of Vivani's current product offerings, citing potential market saturation.
- Recent social media discussions reveal concerns about the company's ability to compete against larger, established players in the industry.
- Community sentiment has shown caution regarding regulatory hurdles that could delay product launches.
- There have been mixed reviews on the efficacy of Vivani's products, raising doubts about long-term market acceptance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VANI Latest News
No recent news available for VANI.
VANI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VANI.
Price Targets
Consensus target: $4.83
VANI MoonshotScore
What does this score mean?
The MoonshotScore rates VANI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest Vivani Medical, Inc. Analysis
Leadership: Adam Mendelsohn
CEO
Adam Mendelsohn serves as the CEO of Vivani Medical, Inc. His background includes extensive experience in the healthcare and medical device industries. He has a proven track record of leading and growing companies, with a focus on developing and commercializing innovative medical technologies. Mendelsohn's expertise spans strategic planning, product development, and commercial operations. His leadership is instrumental in guiding Vivani Medical's strategic direction and driving the company's growth initiatives.
Track Record: Under Adam Mendelsohn's leadership, Vivani Medical has focused on advancing its pipeline of implantable medical devices through clinical trials and regulatory approvals. He has overseen the development of the company's miniature drug implants and visual prostheses, and has been instrumental in securing funding and establishing strategic partnerships. Mendelsohn's strategic decisions have positioned Vivani Medical as a key player in the implantable medical device market.
VANI Healthcare Stock FAQ
What does Vivani Medical, Inc. do?
Vivani Medical, Inc. is a clinical-stage company focused on the development and commercialization of implantable medical devices. The company's primary focus is on developing miniature drug implants for the treatment of chronic diseases and implantable visual prostheses for individuals suffering from blindness. Vivani Medical aims to provide innovative solutions that improve patient outcomes and quality of life by delivering minimally fluctuating drug profiles and restoring useful artificial vision.
What do analysts say about VANI stock?
As of 2026-05-10, analyst coverage of Vivani Medical, Inc. (VANI) is limited due to its clinical-stage nature and relatively small market capitalization. Key valuation metrics are primarily based on future potential revenue and earnings, contingent on successful clinical trial outcomes and regulatory approvals. Growth considerations include the company's ability to secure funding, establish strategic partnerships, and effectively commercialize its products. Analyst consensus is cautiously optimistic, reflecting the potential upside of its innovative implantable device technology.
What are the main risks for VANI?
The main risks for Vivani Medical, Inc. include clinical trial failures, which could delay or halt product development; regulatory hurdles, which could delay or prevent product approvals; competition from established medical device companies, which could limit market share; and limited financial resources, which could constrain growth opportunities. These risks are inherent in the medical device industry, particularly for clinical-stage companies like Vivani Medical.
What are the key factors to evaluate for VANI?
Vivani Medical, Inc. (VANI) holds an AI score of 27/100 (low). Analysts target $4.83 (+273%). Not financial advice.
How frequently does VANI data refresh on this page?
VANI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven VANI's recent stock price performance?
Vivani Medical, Inc. (VANI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative implantable device technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VANI overvalued or undervalued right now?
Valuing Vivani Medical, Inc. (VANI) requires multiple metrics. Analysts target $4.83 (+273%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying VANI?
Before investing in Vivani Medical, Inc. (VANI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- This is not investment advice. Conduct thorough research before making any investment decisions.